In the latest close session, Viking Therapeutics, Inc. (VKTX) was up +1.7% at $28.19. The stock outperformed the S&P 500, which registered a daily gain of 0.83%. Elsewhere, the Dow saw an upswing of 0 ...

Viking Therapeutics VKTX announced that it has initiated the phase III VANQUISH program, evaluating the subcutaneous (SC) ...

Investors in Viking Therapeutics Inc (Symbol: VKTX) saw new options begin trading today, for the August 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...

There are many promising corporations that investors can buy on a dip due to recent market volatility or company-specific ...

Wall Street's smartest money has quietly amassed over $150 million in bullish positions, with Goldman Sachs eliminating all ...

The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly ...

Get the cash flow statement for Viking Therapeutics, Inc. (VKTX). Up to 10 years of financial statements. Quarterly or annual. View as % YoY growth or as % of revenue.

Viking Therapeutics begins Phase 3 trials for VK2735, testing weekly injections in over 5,000 adults with obesity or type 2 diabetes over 78 weeks.

A high-level overview of Viking Therapeutics, Inc. (VKTX) stock. View (VKTX) real-time stock price, chart, news, analysis, analyst reviews and more.